Teva says Phase 3 ecopipam trial halves tic relapse risk in pediatric Tourette syndrome patients
TEVA•Teva said a review of ecopipam studies found the drug halved tic relapse risk versus placebo during continued treatment in pediatric Tourette syndrome patients.
1. Review summarizes trial evidence
A Journal of Child Neurology review synthesized results from completed Phase 2b, Phase 3 and long-term studies of investigational ecopipam in pediatric patients. Across the studies, ecopipam reduced tic severity, sustained benefits over time and lowered relapse risk versus placebo during continued treatment; the review described its D1-selective mechanism as a non-antipsychotic approach with fewer typical D2-therapy tolerability drawbacks.
